Shopping Cart
- Remove All
Your shopping cart is currently empty
Teclistamab (JNJ-64007957) is a human bispecific monoclonal antibody targeting the CD3 receptor expressed on the surface of t-cells and the b-cell maturation antigen (BCMA) expressed on the surface of malignant multiple myeloma b-lineage cells for the treatment of relapsed and refractory multiple myeloma.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $689 | In Stock | |
| 5 mg | $1,590 | In Stock | |
| 10 mg | $2,180 | In Stock | |
| 25 mg | $3,230 | In Stock | |
| 50 mg | $4,370 | 8-10 weeks | |
| 100 mg | $5,890 | 8-10 weeks |
| Description | Teclistamab (JNJ-64007957) is a human bispecific monoclonal antibody targeting the CD3 receptor expressed on the surface of t-cells and the b-cell maturation antigen (BCMA) expressed on the surface of malignant multiple myeloma b-lineage cells for the treatment of relapsed and refractory multiple myeloma. |
| In vitro | Methods: Frozen BM MNCs were treated with Teclistamab (0-532 nM) with or without exogenous healthy T cells to measure target engagement and killing. Results: Teclistamab-induced cytotoxicity in BM MNCs had comparable EC50s (1.5-4.2 nM) in all 3 patient samples; Teclistamab-mediated T cell activation was also similar in all BM MNC samples with EC50s (0.93 - 1.75 nM). [1] |
| Synonyms | JNJ-64007957, JNJ64007957 |
| Cas No. | 2119595-80-9 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.